Scarica l'app Stockscreener
297.96
0.73%
-2.18
Pre-mercato:
308.35
10.39
+3.49%
Precedente Chiudi:
$300.14
Aprire:
$295.86
Volume 24 ore:
200.81K
Relative Volume:
0.56
Capitalizzazione di mercato:
$32.66B
Reddito:
$3.81B
Utile/perdita netta:
$-644.79M
Rapporto P/E:
-47.75
EPS:
-6.24
Flusso di cassa netto:
$-669.77M
1 W Prestazione:
-5.10%
1M Prestazione:
+1.17%
6M Prestazione:
+7.03%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$295.22
$302.40
Intervallo di 1 settimana:
$295.22
$320.00
Portata 52W:
$172.67
$330.63
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Nome
Beone Medicines Ltd Adr
Settore
Industria
Telefono
41-616851900
Indirizzo
C/O BEONE MEDICINES I GMBH, BASEL
Confronta ONC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
297.96 | 35.68B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.05 | 99.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
579.61 | 62.21B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.33 | 59.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
704.07 | 43.33B | 3.06B | 1.28B | 447.35M | 21.30 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-03-03 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-12-03 | Ripresa | Morgan Stanley | Overweight |
| 2024-09-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-02-06 | Ripresa | JP Morgan | Overweight |
| 2023-09-12 | Iniziato | Macquarie | Outperform |
| 2023-08-17 | Iniziato | Jefferies | Buy |
| 2023-07-17 | Iniziato | Citigroup | Buy |
| 2023-06-30 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | Iniziato | Daiwa Securities | Buy |
| 2022-10-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-10-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | Ripresa | JP Morgan | Overweight |
| 2022-03-17 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | Iniziato | Deutsche Bank | Buy |
| 2021-10-12 | Iniziato | Bernstein | Outperform |
| 2021-10-06 | Aggiornamento | CLSA | Underperform → Buy |
| 2021-03-08 | Iniziato | China Renaissance | Buy |
| 2021-03-01 | Downgrade | CLSA | Outperform → Underperform |
| 2020-11-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | Downgrade | Maxim Group | Buy → Hold |
| 2020-11-06 | Downgrade | Piper Sandler | Neutral → Underweight |
Mostra tutto
Beone Medicines Ltd Adr Borsa (ONC) Ultime notizie
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Average Rating of “Buy” from Analysts - Defense World
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Average Recommendation of “Buy” from Analysts - Defense World
Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million - Benzinga
Insider Selling: BeOne Medicines (NASDAQ:ONC) SVP Sells 11,013 Shares of Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) COO Xiaobin Wu Sells 39,936 Shares - MarketBeat
Xiaobin Wu Sells 49,858 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) Sets New 52-Week HighShould You Buy? - MarketBeat
BeOne Medicines (NASDAQ:ONC) Hits New 1-Year High – What’s Next? - Defense World
BeOne Medicines (NASDAQ:ONC) Shares Gap DownShould You Sell? - MarketBeat
BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) CFO Aaron Rosenberg Sells 1,190 Shares - MarketBeat
BeOne Medicines (NASDAQ:ONC) Sets New 12-Month HighWhat's Next? - MarketBeat
BeOne Medicines DRC earnings missed by $0.04, revenue topped estimates - Investing.com India
Analysts Set BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) PT at $327.56 - Defense World
Chan Henry Lee Sells 920 Shares of BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Stock - MarketBeat
Insider Selling: BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Insider Sells 259 Shares of Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) Reaches New 12-Month HighHere's What Happened - MarketBeat
BeOne Medicines stock hits 52-week high at 304.0 USD - Investing.com India
Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End - Ariva
BeOne Medicines stock rises after positive EU opinion for lung cancer drug - Investing.com India
Lai Wang Sells 700 Shares of BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Stock - MarketBeat
Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock? - Yahoo Finance
BeOne Medicines (NASDAQ:ONC) Reaches New 12-Month High After Analyst Upgrade - MarketBeat
BeOne Medicines (NASDAQ:ONC) Reaches New 52-Week High Following Analyst Upgrade - Defense World
BeOne Medicines (NASDAQ:ONC) Shares Gap UpTime to Buy? - MarketBeat
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO Sells $7,044,470.76 in Stock - Defense World
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Rating of “Buy” from Brokerages - Defense World
AFC Gamma (NASDAQ:AFCG) Shares Down 4.9% – What’s Next? - Defense World
BeOne Medicines (NASDAQ:ONC) Stock Price Down 3.6% Following Insider Selling - MarketBeat
BeOne Medicines (NASDAQ:ONC) Receives “Outperform” Rating from Royal Bank Of Canada - Defense World
BeOne Medicines stock rating reiterated at Outperform by RBC Capital - Investing.com
Beone Medicines Ltd Adr Azioni (ONC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.33%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):